Is safety the most important early indicator we can expect from the "handful" of patient results coming? Absence of SAE's is one of the big advantages we hope for from this therapy. This is an early update, with "hopefully at least a handful" of patients results. At this point, maybe the most useful news we are likely to get will be safety related, not so much about efficacy. Hints of efficacy would be welcome, but 5 patients this early can only reveal so much.
Let's not underplay the factor of minimized or absent adverse effects, it is probably what will really set this therapy apart.
News 
Market Data 
Discover 
